Results 161 to 170 of about 16,087 (221)

Dapagliflozin improves hemoglobin and anemia in chronic kidney disease: a systematic review and meta-analysis. [PDF]

Ren Fail
Irvania AN, Tsauri GAA, Yantisetiasti A, Sofiatin Y.   +3 more
europepmc   +1 more source

Risk of urinary tract infection with SGLT2 inhibitor initiation in patients with immune‐mediated inflammatory diseases and type 2 diabetes: A target trial emulation using a Japanese hospital‐based claims database

Journal of Diabetes Investigation, Volume 17, Issue 8, Page 1310-1321, August 2026.
In this target trial emulation of patients with immune‐mediated inflammatory diseases and type 2 diabetes, SGLT2 inhibitor initiation was not associated with a clear increase in UTI risk versus metformin, including across immunosuppressive therapy strata.
Hiroshi Tsushima, Nobuyuki Yajima, Takashi Nomiyama, Ryoko Sakai, Hisashi Noma, Akira Katagiri, Naoto Tamura   +6 more
wiley   +1 more source

Dapagliflozin does not impair microvascular hemorheology in type 2 diabetes mellitus: A multicenter randomized controlled trial (D‐PATH study)

Journal of Diabetes Investigation, Volume 17, Issue 8, Page 1322-1334, August 2026.
Graphical abstract illustrating the study design, physiological rationale, and key findings of the D‐PATH trial. Dapagliflozin, an SGLT2 inhibitor, lowers HbA1c and body weight while increasing hematocrit and erythropoietin levels. Although an elevated hematocrit could theoretically increase blood viscosity and impair microcirculatory flow, ex vivo ...
Yuki Nakatani, Nobuyuki Banba, Shoya Ono, Tomoki Turumi, Megumi Hoshiai, Takushi Sugiyama, Takashi Tomoe, Hajime Tamiya, Naoyuki Otani, Hiroyuki Sugimura, Hidekazu Ikemiyagi, Yusuke Ohya, Koji Yokokawa, Shinichiro Ueda, Yoshimasa Aso, Yasuhiro Maejima, Takanori Yasu   +16 more
wiley   +1 more source

Effect of dapagliflozin on heart failure with reduced ejection fraction in children. [PDF]

Front Cardiovasc Med
Lin S, Chen Y, Zhu D, Wu J, Fu L, Li F, Guo X.   +6 more
europepmc   +1 more source

Effects of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes at Risk of Liver Fibrosis. [PDF]

Diabetes Obes Metab
Oscarsson J, Huhn M, Jiang Y, Gause-Nilsson I, Wiviott SD, Moura FA, Wilding JPH, Cernea S, Van Gaal L, Cahn A, Bhatt DL, Johansson PA, Sjöström CD.   +12 more
europepmc   +1 more source

Effect of Dapagliflozin on Myocardial Fibrosis After STEMI: A Double-Blind, Placebo-Controlled Randomized Trial. [PDF]

J Clin Med
Ortega-Paz L, Laudani C, Morr CI, Sionis A, Vidal-Cales P, Arevalos V, Andrea R, De Diego O, Ortega E, Jimenez-Trinidad FR, Dantas AP, Angiolillo DJ, Sabaté M, Ortiz-Pérez JT, Brugaletta S.   +14 more
europepmc   +1 more source

Effects of Glucagon‐Like Peptide‐1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review

Obesity Reviews, Volume 27, Issue 8, August 2026.
ABSTRACT Introduction Weight loss results in reduced energy expenditure (EE) due to body composition alterations (e.g., fat‐free mass and fat mass losses) and mass‐independent adaptations in EE (e.g., hormones). Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are indicated for obesity management; however, their effects on EE remain unclear ...
Flavio T. Vieira, ZhiDi Deng, Manfred J. Muller, Giovanna G. L. Bergamasco, Sarah Cawsey, Melania Manco, Steven B. Heymsfield, Carla M. Prado, Andrea M. Haqq   +8 more
wiley   +1 more source

Dapagliflozin Protects Cardiomyocytes against Doxorubicin-Induced Toxicity by Modulating Sirtuin 1/Sirtuin 3 and Ferroptosis Pathway. [PDF]

ACS Pharmacol Transl Sci
Khine HEE, Mangmool S, Parichatikanond W.   +2 more
europepmc   +1 more source

Amino acid homeostasis in the kidney: Physiological roles and pathological dysregulation

Physiological Reports, Volume 14, Issue 15, August 2026.
Abstract Amino acids are fundamental to life as protein building blocks and key regulators of metabolism and signaling. The kidney plays a critical, yet underappreciated, role in amino acid homeostasis through three interconnected pillars: selective glomerular filtration, efficient tubular reabsorption, and metabolic processing, which includes de novo ...
Shuo Liu, Caifeng Shi, Yang Zhou, Chunsun Dai   +3 more
wiley   +1 more source

Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Anemia in Patients with Chronic Kidney Disease: A Pre-Post Observational Analysis. [PDF]

Med Sci (Basel)
Gajić S, Simović F, Bontić A, Kezić A, Stojadinović M, Mijušković S, Pavlović J, Ristanović VK, Popović VS, Vićentijević D, Bjeličić M, Petrović K, Mrđa I, Filić K, Shawamri S, Stanković S, Baralić M.   +16 more
europepmc   +1 more source